New Player in the Biosimilars Game: Aurobindo Pharma


Hyderabad, India-based Aurobindo Pharma is the latest addition to the world of biosimilars. The company announced that it has acquired 4 biosimilar products from TL Biopharmaceutical AG. Aurobindo plans to develop and commercialize the 4 molecules after it acquires the early stage data from TL.

An important molecule that the company will acquire with this agreement is the biosimilar for bevacizumab (Avastin), a monoclonal antibody developed by Genentech, which has been approved for treatment of a variety of tumor types: metastatic colorectal cancer, non—small cell lung cancer, platinum-resistant ovarian cancer, advanced cervical cancer, metastatic renal cell carcinoma, and recurrent glioblastoma. Bevacizumab is an angiogenesis inhibitor.

Aurobindo’s managing director, N. Govindarajan, said in a statement that the acquisition falls in line with the company’s strategy of establishing a biosimilar portfolio. Regulatory filings for the new acquisitions, 3 of which are in oncology molecules, are expected between 2020 and 2022.

Related Videos
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
andre harvin
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Andre Harvin, PharmD
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Related Content
© 2023 MJH Life Sciences

All rights reserved.